Getting antibiotic R&D incentives right, from political commitment to impact
Antimicrobial resistance represents one of the most pressing threats to global health, jeopardising many of the advances in medical care that depend on the availability of effective antibiotics.
Most concerningly, the pipeline for new antibiotics is projected to decline further without proper action. At its core, this issue is economic: antibiotics require significant investment to develop, while their use must be carefully managed to preserve their effectiveness.
Policy reform is vital for antibiotic innovation
Without any policy reform, the current antibiotic innovation landscape is unlikely to meet global patient needs. Between now and 2050, resistant infections could be directly responsible for more than 39 million deaths and contribute to 169 million deaths overall,1 with annual healthcare costs potentially rising to USD 159 billion.2
Previous modelling done at IFPMA reinforces the need to act. Maintaining the status quo will lead to a continued decline in the pipeline. However, with the right policy frameworks in place, the trajectory can change, strengthening the number of candidates in clinical development and new approvals over time, and creating a more sustainable market that supports the availability of new antibiotics.
The next UN High-Level Meeting on AMR in 2029 provides an opportunity to move from recognition of the problem to the implementation of effective solutions.
Push and pull incentives must work together
There is broad recognition that both push and pull incentives have a role to play. Push incentives help de-risk research and early development. Yet, they alone cannot address the fundamental challenge at the other end: creating a sustainable market that rewards successful innovation and encourages continued investment.
Building on existing evidence and policy discussions, IFPMA has set out six core principles for the design and implementation of pull incentives. To have meaningful impact, these must provide a sufficient, predictable and sustainable return on R&D investment, helping attract investment back into antibiotic development while supporting the availability of new antibiotics.
Building on both national and international momentum, the period to the next UN High-Level Meeting on AMR in 2029 provides an opportunity to move from recognition of the problem to the implementation of effective solutions.
References
- Naghavi M, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 2024; 404, 1199-1226. tinyurl.com/yc3npedm
- McDonnell, A. et al. 2024. Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans. tinyurl.com/ycyz3fua.
This article was originally published by Media Planet on 18 November 2026.
Author






